Raffit Hassan
Made mesothelin a drug target, from immunotoxins to ADCs and CAR-T, and leads NCI's mesothelioma programme.
Thoracic oncologist whose work on mesothelin biology and mesothelin-directed agents (SS1P, LMB-100, anetumab) underpins current CAR-T and ADC efforts in mesothelioma and pancreatic cancer.
| Title | Journal | Year |
|---|---|---|
| Mesothelin immunotherapy for cancer: ready for prime time? | Journal of Clinical Oncology | 2016 |
Pages like this
not linked directly; found by shared links- PersonBrigitte C. Widemann
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- PersonLouis M. Staudt
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- PersonJames L. Gulley
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- IdeaRegionally delivered mesothelin CAR-T with PD-1 blockade
Shares Mesothelin, Mesothelioma.
- PersonNirali N. Shah
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- PersonPhilip D. Greenberg
- PersonDouglas R. Lowy
Shares NCI Center for Cancer Research (intramural programme), National Cancer Institute (NIH).
- IdeaTreat the body cavity, not the bloodstream, for surface spread
Shares Mesothelin, Mesothelioma.